GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Acrux ACR.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.01

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Acrux — daily ASX:ACR

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Acrux on TradingView ↗
Market value
A$3.2m
Last close × shares
Volume
247k
Shares, 9 Nov 2026

About Acrux

Its shares trade on ASX under the ticker ACR.AX. It has been listed since 29 September 2004. In the fiscal year to 30 June 2026, it reported revenue of A$4.6m and a net loss of A$604,000. At that date it held total assets of A$6.8m and shareholders' equity of A$1.5m.

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The firm's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. The company has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The firm has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.

Figures and description from our data supplier, not checked against the company's own report.

More about Acrux →

Latest on Acrux

Our reporting

We have not reported on Acrux yet.

Next results

2 Mar 2027

Due on 2 Mar 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Acrux's ticker?

Acrux trades as ACR.AX on ASX, under ISIN AU000000ACR3.

What was Acrux's last closing price?

0.01 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Acrux next report results?

Results are expected on 2 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.